Michelle Obale
Nurse Practitioner · Bedford, TXNPI 1619301223
Payments from drug & device makers
Across 100 payments — averaging $25.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$388
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$386
- E.r. Squibb & Sons, L.L.C.$285
- Alkermes, Inc.$280
- Corium, LLC$233
- Lundbeck LLC$162
- plus $841 from 11 others
What the payments were for
- Food & beverage$2,575100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 17 | $388 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $386 |
| E.r. Squibb & Sons, L.L.C. | 10 | $285 |
| Alkermes, Inc. | 8 | $280 |
| Corium, LLC | 8 | $233 |
| Lundbeck LLC | 10 | $162 |
| Otsuka America Pharmaceutical, Inc. | 8 | $145 |
| Teva Pharmaceuticals USA, Inc. | 6 | $145 |
| Tris Pharma Inc | 1 | $115 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $114 |
| Axsome Therapeutics, Inc. | 5 | $99 |
| AbbVie | 4 | $79 |
| Vanda Pharmaceuticals Inc. | 3 | $66 |
| Neurocrine Biosciences, Inc. | 1 | $27 |
| Neos Therapeutics, LP | 1 | $18 |
| Noven Therapeutics, LLC | 1 | $17 |
| Collegium Pharmaceutical, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$456
- CAPLYTA$221
- COBENFY$135
- Dyanavel XR$115
- Quillivant$115
- Quillichew ER$115
How this compares
$2,575 in reported general payments places this provider in the 85th percentile of 5,422 nurse practitioner providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 19 | $158,909 |
| AuvelityDextromethorphan Hbr/Bupropion | 15 | $13,773 |
| Bupropion XlBupropion Hcl | 45 | $1,597 |
| Zolpidem Tartrate | 40 | $794 |
| Alprazolam | 62 | $543 |
| Duloxetine Hcl | 35 | $523 |
| Escitalopram Oxalate | 28 | $496 |
| Fluoxetine Hcl | 29 | $492 |
| Lamotrigine | 13 | $331 |
| Aripiprazole | 18 | $322 |
| Buspirone Hcl | 18 | $165 |
| Clonazepam | 20 | $113 |
| Lithium Carbonate ErLithium Carbonate | 11 | $91 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $27 | $158,90919 claims |
| Axsome Therapeutics, Inc.Auvelity | $99 | $13,77315 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,422 nurse practitioner providers in Texas.
Other nurse practitioner in Bedford
- Jessica MasonBedford$26K
- Cecilia DavisAustin$262K
- Melanie MorrisHouston$254K
- Stephanie BrownHarlingen$235K
- Brittney MisercolaKilleen$223K
- Roger ChapmanTyler$211K
- Kelly BrassilHouston$194K
- Corrie BerkSan Antonio$155K
- Samantha OnealDallas$133K
- Monica WhiteLongview$118K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.